Key terms
About IOVA
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IOVA news
Mar 29
5:12pm ET
Iovance Board Changes: McPeak Retires, Vogt Nominated
Mar 20
6:01am ET
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Coya Therapeutics, Inc. (COYA) and Iovance Biotherapeutics (IOVA)
Mar 14
7:06am ET
Iovance Biotherapeutics (IOVA) Gets a Buy from Piper Sandler
Mar 07
9:31am ET
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)
Mar 07
9:11am ET
Iovance Biotherapeutics price target raised to $26 from $17 at Truist
Mar 07
12:00am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Laboratory (LH), Apellis Pharmaceuticals (APLS) and Iovance Biotherapeutics (IOVA)
Mar 05
2:25pm ET
Positive Outlook for Iovance Biotherapeutics: Buy Rating Justified by Clinical Advancements and Strong Financials
Mar 05
5:12am ET
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Elevance Health (ELV)
Mar 04
6:38am ET
Iovance Biotherapeutics: FDA lifts partial clinical hold on IOV-LUN-202 trial
Mar 01
7:35am ET
Iovance Biotherapeutics (IOVA) Receives a Buy from Truist Financial
Mar 01
7:33am ET
Iovance Biotherapeutics price target raised to $25 from $22 at Wells Fargo
Mar 01
4:57am ET
Iovance Biotherapeutics: Strong Buy on Amtagvi Launch and Positive Growth Prospects
Mar 01
1:17am ET
Iovance Biotherapeutics: Strong Start for Amtagvi and Promising Global Expansion Underpin Buy Rating
Feb 29
11:35am ET
Iovance Biotherapeutics: A Strong Buy on Robust Financials and Promising Clinical Pipeline
Feb 29
9:20am ET
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Merit Medical Systems (MMSI)
Feb 29
8:18am ET
Stifel Nicolaus Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
Feb 29
6:38am ET
Iovance Biotherapeutics price target raised to $22 from $18 at Barclays
Feb 29
6:31am ET
Iovance Biotherapeutics (IOVA) Gets a Buy from Barclays
Feb 29
6:27am ET
Iovance Biotherapeutics: A Strong Buy on Robust Financials and Promising Drug Pipeline
Feb 28
4:24pm ET
Iovance Biotherapeutics reports Q4 EPS (45c), consensus (43c)
Feb 28
10:25am ET
Iovance Biotherapeutics call volume above normal and directionally bullish
Feb 26
7:55am ET
Iovance Biotherapeutics (IOVA) Receives a Buy from Piper Sandler
Feb 25
5:07am ET
Insiders Pour Millions Into These 2 Buy-Rated Stocks; Here’s Why You Might Want to Follow Their Lead
Feb 25
5:07am ET
Insiders Pour Millions Into These 2 Buy-Rated Stocks Here’s Why You Might Want to Follow Their Lead
Feb 25
5:07am ET
Insiders Pour Millions Into These 2 Buy-Rated Stocks — Why You Might Want to Follow Their Lead
Feb 23
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Feb 23
10:45am ET
Iovance Biotherapeutics call volume above normal and directionally bullish
Feb 22
5:04pm ET
Iovance Biotherapeutics Enhances Capital with Share Sale
Feb 22
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 22
8:00am ET
Iovance Biotherapeutics call buyer realizes 55% same-day gains
Feb 21
10:05am ET
Iovance Biotherapeutics call volume above normal and directionally bullish
No recent press releases are available for IOVA
IOVA Financials
Key terms
Ad Feedback
IOVA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IOVA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
